In Vitro Evaluation of Immune Responses in CTCL
This is an in vitro evaluation of cutaneous T-cell lymphoma using patients blood and tissue
to evaluate immune responses related to identified tumor populations and dendritic/ CD 8
cells with the following objectives:
- Objective I: Evaluate the feasibility of the preparation of dendritic cells (DCs), CD8
and Sezary cells (all CD4 positive) in vitro, obtained from the buffy coats or a skin
biopsy from an area with tumor involvement of subjects with cutaneous t-cell lymphoma
(CTCL) and Sezary syndrome (leukemic stage of CTCL) undergoing an approved FDA therapy,
extracorporeal photopheresis (ECP).
- Objective II: Evaluate antigen loading of the DCs.
- Objective III: Test the functional capacities of the DCs derived from CTCL subjects to
overcome immune tolerance to the tumor cells ex-vivo, by using modified Elispot assay
in conjunction with Granzyme B Elispot assay as a measurement of cytotoxicity.
Time Perspective: Prospective
Larisa J. Geskin, M.D.
University of Pittsburgh
United States: Institutional Review Board
|University of Pittsburgh Medical Center||Pittsburgh, Pennsylvania 15213|